Christopher B. Prentiss
Known title: Chief Financial OfficerCIK: 0001717583
Associated companies
Transaction History
| MNKD | ▼ Sell | Tax Withholding | 11,572 | $47K | 7/15/2026 | View on chart |
| MNKD | ▼ Sell | Tax Withholding | 10,675 | $44K | 7/15/2026 | View on chart |
| MNKD | ▼ Sell | Tax Withholding | 12,267 | $34K | 4/22/2026 | View on chart |
| MNKD | ▲ Buy | Grant | 5,000 | $16K | 3/1/2026 | View on chart |
| MNKD | ▼ Sell | Tax Withholding | 11,540 | $44K | 7/15/2025 | View on chart |
| MNKD | ▲ Buy | Grant | 119,000 | $0 | 5/13/2025 | View on chart |
| MNKD | ▲ Buy | Grant | 103,600 | $0 | 5/15/2024 | View on chart |
| MNKD | ▲ Buy | Grant | 129,000 | $0 | 5/15/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
MannKind Presents Furoscix Data at HFSA 2026
MannKind reported new data at the HFSA 2026 conference showing that its Furoscix ReadyFlow autoinjector produced urine output comparable to IV furosemide. The study supports the use of the device for managing edema in patients with heart failure and chronic kidney disease. Truist Securities maintained its rating on the stock but lowered its price target to $5.
MannKind Presents Furoscix Data at HFSA 2026. MannKind reported new data at the HFSA 2026 conference showing that its Furoscix ReadyFlow autoinjector produced urine output comparable to IV furosemide. The study supports the use of the device for managing edema in patients with heart failure and chronic kidney disease. Truist Securities maintained its rating on the stock but lowered its price target to $5.